AIDS Treatment News logo      

July 30, 2009

ddI treatment sole risk factor for noncirrhotic portal hypertension

"Prolonged treatment with ddI (didanosine, Videx) is the sole factor significantly associated with the development of noncirrhotic portal hypertension in HIV-positive individuals, Swiss investigators report in the August 15th edition of Clinical Infectious Diseases.

"The investigators recommend that 'a high index of suspicion is needed in ddI-exposed patients with clinical signs of liver disease'."

Read more in Aidsmap, July 29, 2009.